Abbott Laboratories shares climbed 4.4% in pre-open trading after the company published its second-quarter 2026 financials ahead of the market open. The firm reported Q2 earnings per share of $1.33 and revenue of $12.79 billion, figures that were above consensus forecasts for adjusted EPS of $1.28 and roughly $12.52 billion in revenue.
Company management also indicated that sales of its FreeStyle Libre continuous glucose monitoring (CGM) system are on track to return to double-digit growth - a closely watched metric after prior quarters of investor concern. That upswing in CGM performance, together with the enlarged diagnostics footprint following the acquisition of Exact Sciences, formed the backbone of investor optimism into the report.
Analyst sentiment ahead of the release had been constructive. Benchmark kept a Buy rating and a $120 price target on Abbott the day before the results, modeling Q2 revenue of $12.50 billion in constant currency. Bank of America and RBC Capital had likewise retained Buy ratings in the lead-up to the announcement. A central element for analysts was how the Exact Sciences deal - completed in March 2026 - would show up in Abbott's top line. The acquisition contributed a full quarter of cancer diagnostics revenue and is projected to add roughly $3 billion in incremental sales for 2026, materially enlarging Abbott's diagnostics business.
The broader U.S. market provided little support for sector strength at the same time. The S&P 500 was down 0.3%, the Nasdaq fell 0.9%, and the Dow Jones Industrial Average was modestly positive at 0.1%. There were no major Federal Reserve announcements or notable macroeconomic releases cited as drivers of movement in the healthcare space, and key peers such as Medtronic, Boston Scientific, and DexCom reported no significant earnings catalysts that day. That context suggests Abbott's pre-market advance was driven primarily by its own results and guidance rather than a wider market or industry swing.
The immediate market reaction reflects a clear earnings beat - EPS and revenue figures that outpaced Street consensus - coupled with encouraging commentary about high-growth segments such as FreeStyle Libre and newly enlarged cancer diagnostics. The stock had been trading well beneath its 52-week high of $137.49 prior to this report, and the positive surprise appears to have re-set investor expectations for the back half of 2026.
Analytical note: The report's combination of beat-and-encouraging-segments is the proximate cause of the pre-market rally. The Exact Sciences acquisition providing a full quarter of diagnostics revenue and management's signal that CGM growth will return to double digits are the two discrete operational developments investors appear to be rewarding.